Literature DB >> 9444385

Influence of monomethylfumarate on monocytic cytokine formation--explanation for adverse and therapeutic effects in psoriasis?

K Asadullah1, H Schmid, M Friedrich, F Randow, H D Volk, W Sterry, W D Döcke.   

Abstract

Although the effectiveness of systemic antipsoriatic treatment with fumaric acid esters has been proven, their mode of action is still not understood. Recent results indicate their potency in inducing cytokine production in stimulated T cells. Since monocytes and their cytokines are also considered to be of pathogenic importance in psoriasis, we investigated the effect of monomethylfumarate (MMF) on proinflammatory (TNF-alpha, IL-12) and antiinflammatory (IL-10, IL-1RA) cytokine production by peripheral blood mononuclear cells (PBMC) and separated monocytes. In 24-h PBMC cultures from both psoriatic patients (n = 6-13) and healthy volunteers (n = 7-9), MMF at 100 microM induced secretion of TNF-alpha, IL-10, and IL-1RA. Kinetics of IL-10 protein and mRNA expression indicated de novo production. Moreover, MMF significantly augmented endotoxin-induced synthesis of TNF-alpha, IL-10 and IL-1RA. In contrast, no influence on IL-12 secretion was found. Similar effects of MMF in purified monocytes indicated these cells to be responsible for aberrant cytokine formation. Furthermore, enhanced expression of costimulatory molecules after MMF stimulation confirmed monocyte activation. Multiple restimulation with fumaric acid esters in vitro, however, and immunomonitoring in a patient during Fumaderm initial therapy suggested that initial monocyte activation is followed by subsequent deactivation associated with an antiinflammatory response. Our results may explain the well-known effects of therapy with fumaric acid esters. Thus, initial treatment is often accompanied by adverse effects which may be caused by MMF-induced TNF-alpha formation. The change in the IL-10/IL-12 balance as a result of elective induction of IL-10, however, may have antipsoriatic activity by diminishing type-1/proinflammatory cytokine over-expression and the antigen-presenting capacity of monocytes/macrophages, and by upregulation of IL-1RA.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9444385     DOI: 10.1007/s004030050251

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  24 in total

Review 1.  Dimethyl fumarate in multiple sclerosis: latest developments, evidence and place in therapy.

Authors:  Ralf A Linker; Aiden Haghikia
Journal:  Ther Adv Chronic Dis       Date:  2016-06-10       Impact factor: 5.091

2.  Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration.

Authors:  S Schilling; S Goelz; R Linker; F Luehder; R Gold
Journal:  Clin Exp Immunol       Date:  2006-07       Impact factor: 4.330

3.  IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach.

Authors:  K Asadullah; W Sterry; K Stephanek; D Jasulaitis; M Leupold; H Audring; H D Volk; W D Döcke
Journal:  J Clin Invest       Date:  1998-02-15       Impact factor: 14.808

Review 4.  Safety, tolerability, and efficacy of oral therapies for relapsing-remitting multiple sclerosis.

Authors:  Jiwon Oh; Paul W O'Connor
Journal:  CNS Drugs       Date:  2013-08       Impact factor: 5.749

5.  Improvement of herpetic stromal keratitis with fumaric acid derivate is associated with systemic induction of T helper 2 cytokines.

Authors:  A Heiligenhaus; H Li; A Schmitz; S Wasmuth; D Bauer
Journal:  Clin Exp Immunol       Date:  2005-10       Impact factor: 4.330

6.  Influence of dimethylfumarate on experimental HSV-1 necrotizing keratitis.

Authors:  A Heiligenhaus; H Li; S Wasmuth; D Bauer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-07-06       Impact factor: 3.117

7.  Fumaric Acid and its esters: an emerging treatment for multiple sclerosis.

Authors:  D Moharregh-Khiabani; R A Linker; R Gold; M Stangel
Journal:  Curr Neuropharmacol       Date:  2009-03       Impact factor: 7.363

Review 8.  Regulation of human glia by multiple sclerosis disease modifying therapies.

Authors:  Luke M Healy; Mackenzie A Michell-Robinson; Jack P Antel
Journal:  Semin Immunopathol       Date:  2015-08-11       Impact factor: 9.623

Review 9.  A molecule solves psoriasis? Systemic therapies for psoriasis inducing interleukin 4 and Th2 responses.

Authors:  Kamran Ghoreschi; Ulrich Mrowietz; Martin Röcken
Journal:  J Mol Med (Berl)       Date:  2003-07-18       Impact factor: 4.599

10.  [Successful treatment of skin and lung sarcoidosis with fumaric acid ester].

Authors:  R Gutzmer; A Kapp; T Werfel
Journal:  Hautarzt       Date:  2004-06       Impact factor: 0.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.